CenTrial Logo

Boosting Baby Immunity: Research on Fighting Neonatal Infections


Clinical trial determines that IVIG is not a suitable treatment for neonatal sepsis

A group of scientists have conducted a clinical trial to determine the role of intravenous immunoglobulin (IVIG) in the management of neonatal sepsis.

Neonatal Sepsis

Neonatal sepsis refers to an infection involving the bloodstream in newborn infants less than 28 days old. It is a leading cause of morbidity and mortality among infants, especially in middle and lower-income countries. Researchers have been searching for ways to reduce the risk of neonatal sepsis and one such option is IVIG.

Immunoglobulins are the antibodies produced naturally by the body’s immune system, which help fight infection and disease. Intravenous immunoglobulin, or IVIG, is a treatment that combines immunoglobulins donated by different people to treat various conditions. So essentially, IVIG is a pooled mixture of antibodies derived from different people and can potentially improve the immunity of the recipient.

Clinical Trial

The researchers wanted to find a better treatment for neonatal sepsis. This infection can be really dangerous for babies, and doctors have been using different medicines to treat it. The clinical trial was conducted to see if IVIG could be beneficial for these septic neonates.

The clinical trial involved 80 neonates with clinical features of sepsis. These patients were divided into two groups: one group received 500 mg/kg IVIG while the other group received a placebo. The primary outcome measure was the duration of hospital stay in days. The babies in both groups were comparable in terms of birth weight, gestation, and sex distribution.

Are you interested in clinical trials near you?

You can receive free notification of a trial for this, or any other condition, by completing a short confidential health profile.
Find a clinical trial near me


After treating the babies and watching them closely, the researchers found something really interesting. The babies who got the IVIG did not get any significant benefit in the disease progression. There was no significant difference in the length of hospital stay between the two groups of babies.

Contrary to the previously held notion of IVIG’s effect on the immune system, the results of this clinical demonstrated that IVIG was not a suitable treatment option for neonatal sepsis. This has widespread implications in the treatment of neonatal sepsis as it suggests that IVIG should not be used in these babies.


The results of this clinical trial indicate that IVIG treatment does not provide any help in the management of neonatal sepsis as it does not affect the length of hospital stay and progression of the disease. This emphasizes the need to find better alternatives for the management of this severe condition.
Sage Journals, Jan-18-23

Share this article with a friend:

Get emailed clinical trial results in the categories of your choice:
Free subscription to clinical trial results

Signup to be notified of clinical trials near you that match your condition

Signup and be matched to trials near you
This free service will notify you of current and future clinical trial matches.

This content is for informational and educational purposes only. It is not intended to provide medical advice or to take the place of such advice or treatment from a personal physician. All readers/viewers of this content are advised to consult their doctors or qualified health professionals regarding specific health questions. CenTrial Data Ltd. does not take responsibility for possible health consequences of any person or persons reading or following the information in this educational content. Treatments and clinical trials mentioned may not be appropriate or available for all trial participants. Outcomes from treatments and clinical trials may vary from person to person. Consult with your doctor as to whether a clinical trial is a suitable option for your condition. Assistance from generative AI tools may have been used in writing this article.